Active Not RecruitingNCT05657301
Safety and Tolerability of KH631 Gene Therapy in Participants With Neovascular Age-related Macular Degeneration
PHASE1 · 25 planned enrolment
- Countries listed
- 1
- Registry update
- December 31, 2025
immortal.lifeTrial registrations containing the exact intervention label KH631.
No aliases or equivalent products have been inferred.
This is a registry availability fact, not a safety result, comparison, or conclusion.
Understand the safety boundary →PHASE1 · 25 planned enrolment
PHASE1 · PHASE2 · 42 planned enrolment